In the context of EGFR TKI acquired resistance, the clinical efficacy of dacomitinib in patients with EGFR-mutant lung cancers progressing on first-generation EGFR TKIs that were included in these trials was disappointingly low, with an overall RR of about 8% (Table 2). The gene discussed is EGFR; the disease is lung cancer.